FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

GLENMARK

503.45
+15.7 (3.22%)
Updated 03:29 04/12 IST

GLENMARK Buy or Sell - FrontPage Forums

6 Users have submitted 6 trade ideas of Rs. 3,032,436.54 for GLENMARK
Disclaimer
100% Bullish
0% Bearish

GLENMARK Buy or Sell - Brokerage Reports

No. of reports in last year
6
No. of analysts
4
Average Consensus Forecast
466.67
Consensus Potential
-7.61%
See GLENMARK Share Price Targets >>

GLENMARK Ratings

Long term GLENMARK rating by FrontPage users
3.1/5 (7 Ratings)
Find answers to all your questions on live GLENMARK message board: Is GLENMARK buy or sell? Should I buy GLENMARK shares? Why are GLENMARK shares falling? Should I invest in GLENMARK stock?

  1. Home
  2. GLENMARK Forum

GLENMARK Share Price Discussion

A
Reputation: 17,737 • Today 8:49 AM

Type
Buy
Instrument
GLENMARK DEC20 FUT
Entry Price
₹505
Price@Trade
₹506.75
Target Price
₹550
Stop Price
₹485
Valid Till
Dec 31, 2020 3:20 AM
Margin
₹229,190.69 approx for 1150 Qty
Status
Waiting for entry
Like
Reply

Type
Buy
Instrument
BANKNIFTY 10DEC20 29900 CE
Entry Price
₹480
Price@Trade
₹494.1
Target Price
₹580
Stop Price
₹380
Valid Till
Dec 10, 2020 3:20 AM
Margin
₹240,000 approx for 500 Qty
Status
Waiting for entry
Like
Reply
P
Reputation: 4,966 • Today 8:48 AM
Like
Reply

Type
Buy
Instrument
HDFCBANK DEC20 1300 PE
Entry Price
₹10.9
Price@Trade
₹10.9
Target Price
₹17
Stop Price
₹6.5
Valid Till
Dec 31, 2020 3:20 AM
Margin
₹5,995 approx for 550 Qty
Status
Active
Like
Reply
A
Reputation: -131 • Today 8:47 AM

Type
Buy
Instrument
NIFTY 10DEC20 13300 CE
Entry Price
₹77
Price@Trade
₹77.25
Target Price
₹90
Stop Price
₹66
Valid Till
Dec 4, 2020 3:20 AM
Margin
₹5,775 approx for 75 Qty
Status
Active
Like
Reply (1)
See all replies
TrackerBot @trackerbot
Today 8:48 AM

Update
Trade Entered
Entry Price
₹77
S
Reputation: 7,108 • Today 8:47 AM

Type
Sell
Instrument
SILVERM 26FEB21 FUT
Entry Price
₹64,032
Price@Trade
₹64,032
Target Price
₹63,001
Stop Price
₹64,521
Valid Till
Dec 4, 2020 11:20 AM
Margin
₹46,657 approx for 5 Qty
Status
Active
Like
Reply
Somiish Sukkla in NIFTY-50
#NIFTY50 low made 13153 and out imp level on up...

#NIFTY50 what esle do you want from 13153 to 13253
Like
Reply
D
Reputation: 3,525 • Today 8:46 AM

Type
Buy
Instrument
BANKNIFTY 10DEC20 30500 CE
Entry Price
₹206.85
Price@Trade
₹206.85
Target Price
₹500
Stop Price
₹100
Valid Till
Dec 10, 2020 3:20 AM
Margin
₹413,700 approx for 2000 Qty
Status
Active
Like
Reply
P
Reputation: 259,794 • Today 8:46 AM

Type
Sell
Instrument
CRUDEOIL 18DEC20 FUT
Entry Price
₹3,440
Price@Trade
₹3,435
Target Price
₹3,340
Stop Price
₹3,540
Valid Till
Dec 4, 2020 11:20 AM
Margin
₹1,713,968.75 approx for 500 Qty
Status
Waiting for entry
Like
Reply
P
Reputation: 4,966 • Today 8:46 AM
Like
Reply

Type
Buy
Instrument
ICICIBANK DEC20 540 CE
Entry Price
₹7.45
Price@Trade
₹7.5
Target Price
₹15
Stop Price
₹4
Valid Till
Dec 31, 2020 3:20 AM
Margin
₹10,243.75 approx for 1375 Qty
Status
Active
Like
Reply (1)
See all replies
TrackerBot @trackerbot
Today 8:48 AM

Update
Trade Entered
Entry Price
₹7.45
F
Reputation: 12,782 • Today 8:45 AM

Type
Buy
Instrument
AXISBANK
Entry Price
₹615
Price@Trade
₹614.95
Target Price
₹621
Stop Price
₹612
Valid Till
Dec 7, 2020 3:20 AM
Margin
₹9,840 approx for 16 Qty
Status
Active
Like
Reply (1)
See all replies
TrackerBot @trackerbot
Today 8:46 AM

Update
Trade Entered
Entry Price
₹615
Somiish Sukkla in NIFTY-BANK
#NIFTYBANK 2nd time from 29565 to 29765
Like
Reply
T
Reputation: -21,397 • Today 8:45 AM

Type
Buy
Instrument
NIFTY 31DEC20 14000 CE
Entry Price
₹21.75
Price@Trade
₹21.75
Target Price
₹155
Stop Price
₹1
Valid Till
Dec 31, 2020 3:20 AM
Margin
₹456,750 approx for 21000 Qty
Status
Active
Like
Reply
V
Reputation: 79,559 • Today 8:44 AM

Type
Buy
Instrument
SBIN DEC20 260 CE
Entry Price
₹13.8
Price@Trade
₹13.8
Target Price
₹30
Stop Price
₹2
Valid Till
Dec 31, 2020 3:20 AM
Margin
₹2,070,000 approx for 150000 Qty
Status
Active
Like
Reply

Type
Buy
Instrument
BANKNIFTY 10DEC20 30000 PE
Entry Price
₹323.75
Price@Trade
₹332
Target Price
₹875
Stop Price
₹100
Valid Till
Dec 10, 2020 3:20 AM
Margin
₹809,375 approx for 2500 Qty
Status
Active
Like
Reply (1)
See all replies
TrackerBot @trackerbot
Today 8:45 AM

Update
Trade Entered
Entry Price
₹323.75

Type
Buy
Instrument
BANKNIFTY 10DEC20 30200 CE
Entry Price
₹333  ₹330.75
Price@Trade
₹331.7
Target Price
₹600
Stop Price
₹150
Valid Till
Dec 10, 2020 3:20 AM
Margin
₹661,500 approx for 2000 Qty
Status
Active
Like
Reply (2)
See all replies

Update
Entry Price Modified
Price @ Update
₹329.3
Original Entry Price
₹333
New Entry Price
₹329.3
TrackerBot @trackerbot
Today 8:46 AM

Update
Trade Entered
Entry Price
₹330.75
S
Reputation: 157,849 • Today 8:44 AM

Type
Buy
Instrument
BANKNIFTY 10DEC20 30300 PE
Entry Price
₹320
Price@Trade
₹472.8
Target Price
₹650
Stop Price
₹200
Valid Till
Dec 10, 2020 3:20 AM
Margin
₹4,160,000 approx for 13000 Qty
Status
Waiting for entry
Like
Reply

Type
Buy
Instrument
ICICIBANK DEC20 500 CE
Entry Price
₹21.9
Price@Trade
₹21.9
Target Price
₹50
Stop Price
₹18
Valid Till
Dec 31, 2020 3:20 AM
Margin
₹30,112.5 approx for 1375 Qty
Status
Active
Like
Reply
R
Reputation: 985 • Today 8:43 AM

Type
Sell
Instrument
NICKEL 31DEC20 FUT
Entry Price
₹1,207
Price@Trade
₹1,207
Target Price
₹1,200
Stop Price
₹1,212
Valid Till
Dec 4, 2020 11:20 AM
Margin
₹405,262.5 approx for 3000 Qty
Status
Active
Like
Reply
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 50,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • GLENMARK - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization14,876.17
    Enterprise Value17,679.79
    Price to Earnings14.67
    Price to Book Value1.43
    Return on Capital Employed0.11
    Return on Equity0.1
    Face Value1
    Dividend YieldNA
  • GLENMARK - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    27-Nov-20Geojit Financial ServicesBuy548
    10-Nov-20Nirmal BangBuy578
    9-Nov-20Prabhudas LilladherSell424
    9-Nov-20Motilal OswalNeutral495
    18-Aug-20Prabhudas LilladherSell365
    GLENMARK Brokerage Price Target
  • GLENMARK Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Dec 4490504.7485.5503.25
    Dec 3480489.5479.1487.75
    Dec 2479.15482.05475.5479.7
    Dec 1474.6480.9473.1477.1
    Nov 27471478.8470471.4
  • GLENMARK Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹483.89
    30 Day Moving Average₹483.5
    50 Day Moving Average₹484.18
    100 Day Moving Average₹472.26
    200 Day Moving Average₹400.35
  • GLENMARK - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue6,4037,989.23-0.2
    Operating Profit1,3472,662.19-0.49
    Profit Before Tax1,2192,552.9-0.52
    Net Income1,0142,140.61-0.53
  • GLENMARK - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Shareholder's Funds10,3919,436.620.1
    Total Liabilities5,2694,790.480.1
    Total Assets15,66114,227.10.1
  • GLENMARK - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity1,124877.720.28
    Cash from Investing Activity-1,137-2,580.46-0.56
    Cash from Financing Activity-621,879.38-1.03
    Net Cash Flow-75176.64-1.42
  • GLENMARK - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.060.15
    Return on Equity0.10.23
    Return on Capital Employed0.110.22
  • GLENMARK - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue0.23
    3 Year CAGR Growth in Operating Profit0.04
    3 Year CAGR Growth in EBIDTA0.11
    3 Year CAGR Growth in Net Income0.01
    3 Yr CAGR Growth - Diluted EPS-0.03
  • GLENMARK - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue2.16
    5 Year CAGR Growth in Operating Profit3.05
    5 Year CAGR Growth in EBIDTA2.4
    5 Year CAGR Growth in Net Income1.63
    3 Yr CAGR Growth - Diluted EPS1.52
  • GLENMARK - Recent News

    keyboard_arrow_down
    NewsBot
    Dec 1 6:53 AM
    Glenmark Pharma share price gains on tentative USFDA nod for kidney cancer drug
    Moneycontrol
    NewsBot
    Dec 1 6:03 AM
    Glenmark Pharma gets tentative nod from USFDA for cancer treatment drug
    Moneycontrol
    NewsBot
    Dec 1 5:11 AM
    Glenmark Pharma gets tentative nod from USFDA for cancer treatment drug
    The Economic Times
    NewsBot
    Nov 28 5:11 AM
    Dr Reddy's to acquire select brands from Glenmark in Russia, Ukraine
    The Economic Times
    NewsBot
    Nov 23 8:21 AM
    Study shows Favipiravir provides multiple benefits in COVID-19 treatment: Glenmark
    The Economic Times
    NewsBot
    Nov 23 8:03 AM
    Study shows Favipiravir provides multiple benefits in COVID-19 treatment: Glenmark Pharmaceuticals
    Moneycontrol
    NewsBot
    Nov 12 11:58 AM
    Buy Glenmark Pharmaceuticals: target of Rs 635: ICICI Direct
    Moneycontrol
    NewsBot
    Nov 11 5:33 AM
    Glenmark Pharma gets USFDA nod for Tacrolimus capsules
    Moneycontrol
    NewsBot
    Nov 11 4:56 AM
    Glenmark Pharma gets USFDA nod for Tacrolimus capsules
    The Economic Times
    NewsBot
    Nov 10 4:26 AM
    Neutral on Glenmark Pharma, target price Rs 495: Motilal Oswal
    The Economic Times
  • GLENMARK - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. NS...
    Cipla Ltd. NSE: CIPLA | BSE: 500087 |...
    Aurobindo Pharma Ltd. NSE: AUROPHARMA...
    Biocon Ltd. NSE: BIOCON | BSE: 532523...
    Lupin Ltd. NSE: LUPIN | BSE: 500257 |...
    Dr. Reddy's Laboratories Ltd. NSE: DR...
    Piramal Enterprises Ltd. NSE: PEL | B...
    Divi's Laboratories Ltd. NSE: DIVISLA...
    Cadila Healthcare Ltd. NSE: CADILAHC ...
    Apollo Hospitals Enterprise Ltd. NSE:...
  • GLENMARK - More Information

    keyboard_arrow_down

    Glenmark Pharmaceuticals Ltd:
    Glenmark Pharmaceuticals, a company that deals with pharmaceutical products, was established in 1977 by Gracias Saldanha which headquarter is in Mumbai, India. It manufactures generic drugs and various active pharmaceutical ingredients.
    The company was named after the name of his two sons, Glenn and Mark. In the beginning, the company used to sell the products in India, Africa, and Russia. The company came to the public in the year 1999, and also took some procedures and built its research facility for the first time. Glenmark Saldanha’s elder son Glenn had the invasion as the CEO of the company in 2001 after working at PricewaterhouseCoopers when he came back to India.
    In 2008, Glenmark became the fifth-biggest company for pharmaceuticals in India. Glenmark entered into the market of dermatology by launching ‘Candid Cream’. Dermatology is one of the key focus areas of Glenmark, until today.
    About Company Information:
    The company entered the market of dermatology by launching Candid Cream in 1979, at the very beginning. In 1980, the company began to export their products outside of the country. In 1983, it incorporated its manufacturing facility for the very first time at Nasik, Maharashtra.
    The R&D department was founded in the plant at Nasik in 1984. The company introduced Ascoril in the market in 1987. The company initiated operating its business in Srilanka, Afghanistan, Mauritius, and Kenya in 1989. It expanded the plant at Nasik in 1992. It integrated a wholly possessed subordinate company, Glenmark Exports Pvt Ltd to strengthen its position internationally in the market of pharmaceuticals in 1996.
    In Brazil, the company started to sell pharmaceutical products in 1999. The company entered into the segment of diabetes in 2000. The company initiated the business of manufacturing API in 2001. It obtained a facility of API manufacturing from Glaxosmithkline Pharmaceuticals at Ankleshwar, Gujarat in 2002. Glenmark has done its out-licensing deal for the first time to discover R&D in 2004.
    The company commissioned a new facility for manufacture at Baddi, Himachal Pradesh in 2005. It signed an out-licensing contract with Merk KGaA, Germany in 2006, for Melogliptin. The company received the approval of MHRA, the UK for their plant at Baddi in 2007.
    The company re-organized its business and integrated a company namely Glenmark Generics as its subordinate one in 2008. During 2009-10, it integrated Glenmark Generics B.V. in the Netherlands. Glenmark signed the Development Agreement with Forest Laboratories to collaborate on Novel Agents.
    The company made the announcement of launching a cream namely Hydrocortisone Butyrate in the US, in 2013. Glenmark brought together its two subsidiary companies which are Glenmark Generics Ltd. and Glenmark Access Ltd. with GPL in the year 2014. The company disclosed its approval and launching of Verapamil and Trandolapril Hydrochloride in 2015.
    Glenmark announced the strategic blueprint of its evolution to an innovation-led globally spread pharmaceutical organization on 19th December 2016. The blueprint bears its greater alignment of business spreading generics to give priority mostly to the research and development efforts in three core therapeutic sections: respiratory, oncology and dermatology.
    The company announced affirmative results for GSP 301 on 30th March 2017. The company has also announced that it has submitted an NDA to the FDA of US for Ryaltris, the respiratory pipeline candidate, which is basically a tentative fixed-dose nasal spray which is a combination of a steroid and an antihistamine that is used for treatment of seasonal allergic rhinitis (SAR) and it was announced on 22nd May 2018.
    The company announced on 19th June 2018 that the first supplemental Abbreviated New Drug Application (SANDA) was provided by the US Food and Drug Administration for the manufacturing facility of the company in Monroe, New Carolina. The Monroe facility in New Carolina is the first manufacturing plant of Glenmark in the US which is founded to manufacture various pharmaceutical products of fixed does. The company has made an investment of more than $100 million on that facility along with some planning of further development in upcoming years.
    How Glenmark Pharmaceuticals Ltd is categorised as Pharmaceuticals and Health Care Sector and Pharmaceuticals Industry.
    Pharmaceuticals and Health care sectors consist of firms involved in the medical space. It is one of the multiple sectors that comprise a range of businesses, including ones that offer medical services directly, or to those that work to develop, create and market medical equipment and medicines. It also includes the other services that provide medical insurance and other related products, and many more. The stocks of health care companies mostly have mixed performance. It is due to the inherent challenges to the industry each year, regulatory uncertainties, fiscal policy concerns, and more.
    Glenmark Pharmaceuticals Ltd is categorized under the Pharmaceutical and Health care sector and Pharmaceutical Industry. The Pharmaceutical Industry includes companies that derive their business by researching, discovering, developing, manufacturing, and marketing and distributing pharmaceutical medicines and drugs.
    Glenmark Pharmaceuticals Ltd, Competitors and Sector Peers:
    Abbott India Ltd. ABBIND
    Alembic Ltd. ALELTD
    Alembic Pharmaceuticals Ltd. ALEPHA
    Alkem Laboratories Ltd. ALKLAB
    Alpa Laboratories Ltd. ALPLAB
    Ambalal Sarabhai Enterprises Ltd. AMBSAR
    AstraZeneca Pharma India Ltd. ASTZEN
    Bafna Pharmaceuticals Ltd. BAFPHA
    Bajaj Healthcare Ltd. BAJHEA
    Biocon Ltd. BIOLTD
    Cian Healthcare Ltd.
    Cipla Ltd. CIPLTD
    Concord Drugs Ltd. CONDRU
    Dishman Pharmaceuticals & Chemicals Ltd.[Merged] DISPHA
    Divi's Laboratories Ltd. DIVIL
    Dr. Reddy's Laboratories Ltd. DR
    GlaxoSmithKline Pharmaceuticals Ltd. GLAPHA
    Glenmark Pharmaceuticals Ltd. GLEPHL
    IOL Chemicals and Pharmaceuticals Ltd. IOLCHE
    Lincoln Pharmaceuticals Ltd. LINPHA
    Lupin Ltd. LUPLTD
    Madhuveer Com 18 Network Ltd. TOHPHA
    Mahavir Advanced Remedies Ltd. INDAME
    Makers Laboratories Ltd. MAKLAB
    Natco Pharma Ltd. NATPHA
    Natural Capsules Ltd. NATCAP
    Ranbaxy Laboratories Ltd. RANLAB
    Sanofi India Ltd. AVEPHA
    Sharon Bio-Medicine Ltd. SHAPHA
    Sun Pharmaceutical Industries Ltd. SUN28
    Zenith Healthcare Ltd. ZENHEA
    Zyden Gentec Ltd. ZYDGEN
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.

PrivacyTerms
FrontPage © 2020